A phase Ia/Ib study to evaluate the taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer

Trial Profile

A phase Ia/Ib study to evaluate the taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Taselisib (Primary) ; Fulvestrant
  • Indications Breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 18 Mar 2017 Results (n=171) of retrospective pooled analysis of PMT4979g and JO29196 trials assessing effect of acid reducing agent on PK of taselisib, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 30 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
    • 22 May 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top